TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05769049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REC610
Description: administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Shingrix
Study: NCT06453317

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
Study: NCT05076838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Nasal Spray [Valtoco]
Description: 5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
Study: NCT05141409

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: Artificial Intelligence

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: Artificial Intelligence
Study: NCT05766566

Intervention type: PROCEDURE
Intervention: Perianal fistula surgery
Description: surgical treatment of the perianal fistula through curettage, closure with suture thread (vicryl 2/0) of the internal orifice and lipofilling of the passage with microfragmented autologous adipose tissue processed with the Lipogems® system.
Study: NCT06353763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality learning program
Description: The immersive virtual reality learning programme was developed by the research team and two nurse experts in chronic wounds, who designed the learning content and script and created six pressure ulcer (PU) cases. Based on the standards of the European Pressure Ulcer Advisory Panel (EPUAP), the National Pressure Ulcer Advisory Panel (NPUAP) and the National Group for the Study and Advice on Pressure Ulcers and Chronic Wounds (GNEAUPP), prevention of healthy skin (case one), management of grade I, II, III and IV PUs (cases two to five) and an infected PU (debridement intervention) were developed. For each case, there was a formative version with immediate feedback and an evaluative one. Before starting the training, the students learned how to use the virtual reality glasses, buttons and joystick by playing a game that trained different dexterity movements. The computer assembly IVR application was developed using Unity 3D and the virtual objects were designed in 3Ds Max.
Study: NCT04610333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified MBSR programme
Description: 1 hour group session once a week in 10 weeks
Study: NCT06550570

Intervention type: BEHAVIORAL
Intervention: QEVA questionnaire
Description: QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)

Intervention type: BEHAVIORAL
Intervention: QEVA questionnaire
Description: QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)
Study: NCT06285292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMY
Description: Patients in the intervention group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study
Study: NCT05596006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASIMOMMY®
Description: ASIMOMMY 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidon
Description: Domperidone capsule 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of placebo 500mg.
Study: NCT04867044

Intervention type: OTHER
Intervention: STUDY
Description: One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
Study: NCT06453317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
Study: NCT06256926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)
Description: Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
Study: NCT05371548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAM mobile application
Description: See description of intervention group
Study: NCT05771038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using sodium alendronate gel
Description: sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using sticky bone
Description: sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed
Study: NCT06095167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: without concurrent cisplatin chemotherapy
Description: IMRT without concurrent cisplatin chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: with concurrent cisplatin chemotherapy
Description: IMRT with concurrent cisplatin chemotherapy
Study: NCT05650671

Intervention type: DEVICE
Intervention: instrumented wheelchair
Description: Measurements of pressure, temperature and humidity at the subject/cushion interface
Study: NCT04867044

Intervention type: OTHER
Intervention: Control
Description: healthy woman volunteers
Study: NCT05792566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atomic app
Description: Using the Atomic app to improve physical activity
Study: NCT05822050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: XPO1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: XPO1 inhibitor
Study: NCT04975854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (Virtual Reality)
Description: Virtual reality scenarios consists of increasingly intense exposures to phobic stimuli (e.g., looking over railings from various floor levels) with the support of the therapist. The goal of VRET is sufficient reduction in anxiety to allow the patients to expose themselves to heights in everyday situations.

Intervention type: OTHER
Group type: OTHER
Intervention: Information Session
Description: This includes 20-minute information session about general principles of exposure therapy before the start of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Session
Description: This includes 20-minute information session about general principles of exposure therapy before the start of the study.
Study: NCT06212544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: Enhanced microeconomic intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention
Description: Usual care and then access to enhanced microeconomic intervention
Study: NCT05532033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: A device able to delivery high flow oxygen therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask
Description: standard oxygen therapy
Study: NCT05806840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Adaptation to Prevent Drug Use (RAPD)
Description: RAPD will include a novel bundle of implementation strategies to support rapid responses to urgent drug use events. The strategies deployed will be based on the first step of the After Action Review: critical analysis and reflection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation
Description: Standard implementation of the Michigan Model for Health (MMH) includes curriculum materials and as-needed technical assistance provided by a school health coordinator.
Study: NCT06227767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal stabilization exercise
Description: The exercise program will be implemented in the hospital under the supervision of a physiotherapist for 6 weeks, and the next 6 weeks will be followed as a home program. The first group will be given an exercise program 2 days a week, the second group will be given an exercise program 4 days a week. The exercise program is planned to be 40 minutes and the first 5 minutes of the program will be warm-up and the last 5 minutes will be cool-down exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal stabilization exercise
Description: The exercise program will be implemented in the hospital under the supervision of a physiotherapist for 6 weeks, and the next 6 weeks will be followed as a home program. The first group will be given an exercise program 2 days a week, the second group will be given an exercise program 4 days a week. The exercise program is planned to be 40 minutes and the first 5 minutes of the program will be warm-up and the last 5 minutes will be cool-down exercises.
Study: NCT04601571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CORTRAK Stylet
Description: The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
Study: NCT05603325

Intervention type: OTHER
Intervention: Person Centered Practice
Description: Staff will be asked to:~* Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~* Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~* Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~* Attend a final focus group to evaluate the workshop programme.

Intervention type: OTHER
Intervention: Interview
Description: Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
Study: NCT05921552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
Study: NCT05322122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Side-to-side anastomosis duodeno-ileostomy diversion procedure
Description: Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
Study: NCT05493501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib monotherapy
Description: Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib monotherapy
Description: Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib monotherapy
Description: 80 mg tablet administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Administered by IV Infusion given over 4 fixed cycles per prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by IV Infusion over 4 fixed cycles per prescribing information.
Study: NCT05133674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Description: i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
Study: NCT05082974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline 0.6mg/ml) nasal spray
Description: OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray \[control\]
Study: NCT05282563

Intervention type: PROCEDURE
Group type: OTHER
Intervention: double and a half layered esophagojejunal anastomosis
Description: After the end of esophagojejunostomy, 3/0 barbed suture or absorbable suture was used. First, the anastomotic site was sutured continuously for one circle, with the suture spacing of 3-4 mm and the width of 4-5 mm. Then, the continuous horizontal mattress type seromuscular layer varus suture was used to embed the anastomotic stoma for one circle, and the suture width was 5\~8 mm above and below the anastomotic stoma. After the completion of esophagojejunostomy, the full-thickness reinforcement of the anastomosis and the embedding of the seromuscular layer can ensure the complete anastomosis of the mucosal layer of the anastomosis. The embedding of the seromuscular layer can also improve the anti-pressure and anti-tension of the anastomosis, and provide a guarantee for the primary healing of the anastomosis.
Study: NCT05379842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education on a healthy lifestyle and health literacy
Description: Traditional motivational face-to-face workshops with lifestyle (nutritional, physical activity, sleep) advice every 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education on a healthy lifestyle and health literacy
Description: E-learning and digital (with videos -YouTube channel or WhatsApp/text message) educational workshops with lifestyle (nutritional, physical activity, sleep) advice every 15 days
Study: NCT05327504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Topic Writing
Description: Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
Study: NCT05523375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines.
Study: NCT04921332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) Lamp
Description: With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
Study: NCT05648370

Intervention type: GENETIC
Intervention: ctDNA testing and whole exome sequencing
Description: Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
Study: NCT05614921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided external oblique intercostal plane block
Description: ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: 5 ml local anesthetic for each trocar side
Study: NCT05257707

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular biology
Description: Samples will be taken as part of routine care consultations. These include~* Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~* Blood samples taken to isolate plasma, cells or serum.~* CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~* Urine samples collected in sterile ECBU jars.~* Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~* Surgical parts.~* Eyebrows.~* Saliva samples or gargle samples.
Study: NCT05730972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous electrical acupoint stimulation
Description: The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Routine palliative treatment
Description: The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine palliative treatment
Description: The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
Study: NCT05540782

Intervention type: BEHAVIORAL
Intervention: PROMIS-SF v2.0 -Cognitive Function 8a
Description: Patient-Reported Outcomes (PROs)